Biogen Inc. (NASDAQ:BIIB) finished Friday with an addition of $0.92 to close at $276.92, an upside of 0.33 percent. An average of 603,760 shares of common stock have been traded in the last five days. There was a fall of -$3.69 in the past week, and it reached a new high 16 times over the past 12 months. The last 20 days have seen an average of 1,077,675 shares traded, while the 50-day average volume stands at 1,283,302.
BIIB stock has decreased by -9.26% in the last month. The company shares reached their 1-month lowest point of $272.20 on 12/30/22. With the stock rallying to its 52-week high on 11/30/22, shares of the company touched a low of $187.16 and a high of $311.88 in 52 weeks. It has reached a new high 15 times so far this year and achieved 15.42% or $37.00 in price. In spite of this, the price is down -11.21% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
BIIB stock investors should be aware that Biogen Inc. (BIIB) stock had its last reported insider trading activity 47 days ago on Nov 14. In this transaction, the insider spent $1,683,617. EVP Chief Legal Off & Corp Sec, ALEXANDER SUSAN H, disposed of 5,532 shares at a price of $280.70 on Oct 27. The insider now owns more than $1,552,832 worth of shares. Prior to that, 10% Owner BIOGEN INC. went on to Sale 100,000 shares at $5.27 each on Aug 30. An amount of $526,520 was transacted.
Biogen Inc. (BIIB) has a trailing price-to-earnings (P/E) ratio of 14.11. The stock’s beta is 0.23. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.87, the price-to-book (PB) ratio at 3.13, and the price-to-cash flow ratio at 17.87.
The quick ratio of Biogen Inc. for the three months ended September 29 was 2.10, and the current ratio was 2.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.49 and a total debt to equity ratio of 0.49 for the quarter ending September 29. Its gross profit as reported stood at $8.87 billion compared to revenue of $10.98 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Biogen Inc.’s return on assets was 11.80%.
For the three-month period that ended September 29, Biogen Inc. had $1.24 billion in cash and short-term investments compared to $6.28 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $1.13 billion in the quarter, while revenues were grew 70.99%. The analyst consensus anticipated Biogen Inc.’s latest quarter earnings to come in at $4.14 per share, but it turned out to be $4.77, a 15.20% surprise. For the quarter, EBITDA amounted to $1.44 billion. Shareholders own equity worth $144.0 million.
From a technical analysis perspective, let’s take a brief look at Biogen Inc. (BIIB) price momentum. RSI 9-day as of the close on 30 December was 35.42%, suggesting the stock is Neutral, with historical volatility in this time frame at 15.39%.
As of today, BIIB’s price is $276.18 -1.31% or -$3.69 from its 5-day moving average. BIIB is currently trading -8.26% lower than its 20-day SMA and +27.27% higher than its 100-day SMA. However, the stock’s current price level is +4.72% above the SMA50 and +35.88% above the SMA200.
The stochastic %K and %D were 14.19% and 11.10%, respectively, and the average true range (ATR) was 5.98. With the 14-day stochastic at 20.99% and the average true range at 6.50, the RSI (14) stands at 40.09%. The stock has reached -4.37 on the 9-day MACD Oscillator while the 14-day reading was at -7.17.
Goldman upgraded Biogen Inc. (NASDAQ: BIIB) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Biogen Inc. (BIIB) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BIIB, while 12 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 19 others rate it as a “buy”.
What is BIIB’s price target for the next 12 months?
Analysts predict a range of price targets between $247.00 and $370.00, with a median target of $325.00. Taking a look at these predictions, the average price target given by analysts for Biogen Inc. (BIIB) stock is $321.50.